EMQN CIC

Established in 1998 and based on the Manchester Science Park, EMQN CIC is a not-for-profit organisation community interest company (CIC; Limited by guarantee and registered in England and Wales (Companies House Registration: 12020789)) promoting quality in genomic testing by establishing, harmonising and disseminating best practice through the provision of External Quality Assessment (EQA) activities.

EMQN CIC provide accredited (ISO 17043) EQA schemes to laboratories worldwide in collaboration with many organisations including EuroGentest, CF Network , GenQA, ESP EQA, Gen&Tiss, CSCQ, AIOM, RCPA QAP, QUipP, RfB and the EAA.

EMQN CIC provides a comprehensive range of genomics quality assurance programs to laboratories and industry worldwide. It is committed to helping ensure diagnostic genomic laboratory test results are accurate, reliable and comparable wherever they are produced.

The schemes covered by EMQN CIC relevant to IQNPath  include:

EQA’s for Somatic mutation testing in tissue and plasma including:

  • Breast cancer (PIK3CA) [Tissue]
  • Colorectal cancer [Tissue]
  • Lung cancer [Tissue]
  • Lung cancer [Plasma]
  • Melanoma [Tissue]
  • Microsatellite Instability
  • Oncogene Panel Testing
  • Ovarian and Prostate Cancer (PARPi) [Tissue]
  • Ovarian, Breast, Pancreatic and Prostate Cancer (PARPi) [DNA]
  • Prostate Cancer (PARPi) [Plasma]

EQA’s for germline testing in inherited cancers:

  • Hereditary Cancer Panel Testing
  • Hereditary Breast and Ovarian Cancer
  • Lynch Syndrome (Hereditary non-polyposis colon cancer)
  • Multiple Endocrine Neoplasia Type 2
  • Polyposis Syndromes (FAP, MAP)
  • Retinoblastoma
  • Von Hippel Lindau SyndromeMolecular testing in Liquid Biopsy

EQA’s for techniques used in molecular testing:

  • Pharmacogenetics
  • Postnatal CNV detection
  • DNA Sequencing – NGS (Germline)
  • DNA Sequencing – NGS (Somatic + matched germline sample)
  • DNA Sequencing – NGS (Somatic – no matched germline sample)
  • DNA Sequencing – Sanger
  • Non-invasive prenatal testing (NIPT) for aneuploidies
  • Non-invasive prenatal testing (NIPT) for sex determination

For detailed information on our portfolio of services, please go to our website to access our EQA catalogue HERE . EMQN is a UKAS accredited provider of EQA services.

For more information please visit the EMQN website.